Abstract

Summary

This dissertation describes the development of photoswitch molecules (AAQ and DENAQ) that restore light sensitivity to degenerated retinas without requiring gene therapy, offering a potential clinical treatment for blinding diseases like retinitis pigmentosa and age-related macular degeneration. DENAQ is particularly notable for responding to broad-spectrum white light and acting selectively on damaged retinas, sparing healthy tissue, which could enable treatment of partial as well as complete vision loss.
Abstract

Key Findings

  • AAQ photoswitch restored electrical retinal light responses, the pupillary light reflex, and simple visual behaviors in blind mice with retinitis pigmentosa.
  • DENAQ demonstrated improved light sensitivity and persistence compared to AAQ, responds to broad-spectrum white light, and selectively targets retinas with photoreceptor cell death while leaving healthy retinas unaffected.
  • The optopharmacological approach requires no viral gene therapy or invasive surgery, reducing clinical risk compared to optogenetic alternatives.
Categories

Categories

Eye Health & Vision: The paper develops optopharmacological treatments (AAQ, DENAQ photoswitch molecules) to restore light sensitivity in retinas affected by retinitis pigmentosa and age-related macular degeneration.
The Science of Light: The research advances understanding of light-sensitive molecular mechanisms in retinal neurons, including voltage-gated ion channels and photoreceptor biology, relevant to light detection and phototransduction.
Authors

Author(s)

I Tochitsky
Publication Date

Publication Year

2013
View more publications